Elevance Health Q3 2026 Earnings: Revenue Grew, Operating Income Did Not

Farzin Espahani

Strategic Advisor, Insurance Growth, Medicare Distribution, and Compliance

Published October 23, 2026

Elevance Health is one of the largest health insurance companies in the United States. It operates health benefits plans under the Anthem brand in 14 states and serves members across Medicaid, Medicare, and commercial markets. Its Carelon subsidiary provides pharmacy benefits management, behavioral health, and other health services to Elevance plans and external clients. [1]

My reading of Elevance's Q3 2026 results is that the company is managing a structural problem: revenue is growing, but medical costs are growing faster. The benefit expense ratio has risen in each of the last five quarters. The Health Benefits segment, which generates most of the company's operating income, is absorbing the majority of that pressure. Carelon is growing but is not yet large enough to offset the margin compression in health benefits.

The guidance reduction from at least $27 to at least $26 per share is a signal that management does not expect a rapid reversal in the near term. The five-year comparison shows how far the margin has moved from its 2022 and 2023 levels.

Elevance Q3 five-year earnings comparison, 2022 through 2026

The table compares the three months ended September 30 in each year. Dollar figures are in millions, except per-share amounts. GAAP applies to reported income figures; adjusted EPS is Elevance's supplemental non-GAAP measure.

Sources: Elevance Health Q3 earnings releases for 2022, 2023, 2024, 2025, and 2026. VHealth calculations: operating margin = operating income / operating revenue. Membership figures are approximate from earnings releases.

Revenue grew, but operating income fell in every year since 2023

From Q3 2022 to Q3 2026, Elevance grew operating revenue 47.3 percent, from $38.5 billion to $47.7 billion. Over the same period, operating income fell 26.5 percent, from $1.84 billion to $1.35 billion. Net income fell 40.5 percent, from $1.50 billion to $891 million. [2] [1]

The operating margin peaked at 4.8 percent in Q3 2022 and Q3 2023. It has declined in each subsequent year, reaching 2.8 percent in Q3 2026. The benefit expense ratio moved in the opposite direction, rising from 86.0 percent in Q3 2022 to 91.2 percent in Q3 2026.

The operating cost ratio improved from 9.8 percent to 8.1 percent over the same period, reflecting administrative efficiency gains. Those gains have not been sufficient to offset the benefit expense ratio increase. For every dollar of administrative cost saved, more than a dollar of additional medical cost has been added.

Benefit expense ratio by segment, Q3 2022 through Q3 2026

The benefit expense ratio measures medical costs as a percentage of premium revenue. The segment breakdown shows where the pressure is concentrated.

Sources: Elevance Health Q3 segment disclosures for 2022 through 2026. Government business includes Medicaid and Medicare. Commercial business includes employer-sponsored and individual market plans.

Government business drove the consolidated ratio higher in each year. Its benefit expense ratio reached 94.3 percent in Q3 2026, meaning that for every $100 of government premium revenue, $94.30 was spent on medical care before any administrative cost. Commercial business also rose, from 82.1 percent to 86.2 percent, but the increase was smaller and the starting point was lower.

The gap between government and commercial benefit expense ratios widened from 6.1 percentage points in Q3 2022 to 8.1 percentage points in Q3 2026. That widening reflects the different dynamics of Medicaid reimbursement rates, Medicare Advantage payment rates, and commercial pricing flexibility.

Health Benefits segment operating margin, Q3 2022 through Q3 2026

The Health Benefits segment generates most of Elevance's operating income. Its margin decline explains most of the consolidated operating margin compression.

Sources: Elevance Health Q3 segment disclosures, 2022 through 2026. VHealth calculation: operating margin = operating income / operating revenue.

Health Benefits operating income fell from $1.56 billion in Q3 2022 to $492 million in Q3 2026, a decline of 68.5 percent. Revenue grew 23.8 percent over the same period. The segment's operating margin fell from 5.5 percent to 1.4 percent.

At 1.4 percent, the Health Benefits margin leaves limited room for unexpected cost increases, investment in member services, or provider contract disputes. A benefit expense ratio that rises another 50 basis points would eliminate most of the remaining margin at current revenue levels.

Carelon revenue and margin, Q3 2022 through Q3 2026

Carelon provides pharmacy benefits management, behavioral health, and other health services. It serves Elevance plans and external clients. Its revenue growth has been consistent, but its margin has narrowed.

Sources: Elevance Health Q3 segment disclosures, 2022 through 2026. VHealth calculation: operating margin = operating income / operating revenue.

Carelon revenue grew 33.7 percent from Q3 2022 to Q3 2026. Operating income grew 7.3 percent over the same period. The margin held at 5.6 percent through Q3 2024, then declined to 4.9 percent in Q3 2025 and 4.5 percent in Q3 2026.

Carelon's operating income of $891 million in Q3 2026 was nearly equal to the consolidated operating income of $1.35 billion, meaning the Health Benefits segment contributed only $459 million net after Carelon's contribution and corporate eliminations. That ratio illustrates how dependent consolidated earnings have become on the services segment as health benefits margins compress.

Medicare Advantage membership decline and its effect on the business mix

Elevance reported approximately 1.73 million Medicare Advantage members at September 30, 2026, down 16.8 percent from approximately 2.08 million a year earlier. The decline reflects deliberate market and product decisions rather than purely competitive losses. [1]

Management has stated that it will prioritize margin over enrollment volume in Medicare Advantage. That approach accepts lower membership in exchange for better per-member economics. The risk is that fixed costs are spread over a smaller base, and that network and provider relationships built for a larger membership become harder to maintain.

The membership decline also affects the business mix. Government business, which carries a higher benefit expense ratio than commercial business, is a smaller share of the total. That shift should, over time, reduce the consolidated benefit expense ratio. The Q3 2026 results do not yet show that effect, because Medicaid cost trends have offset the Medicare Advantage reduction.

What payer and provider leaders should watch in the recovery

Elevance reaffirmed its full-year 2026 operating revenue guidance of approximately $190 billion and lowered its adjusted EPS guidance to at least $26 per share. Management described the Q3 results as reflecting the expected trajectory of medical cost trends and indicated that 2027 planning would incorporate current cost experience. [1]

For payer, provider, and distribution leaders, I would judge the recovery against four operating tests.

Elevance's next results should show whether the benefit expense ratio has stabilized and whether the Health Benefits margin has recovered from 1.4 percent. The stronger evidence of recovery would be a declining government business benefit expense ratio alongside stable or growing Carelon margins. A guidance increase would confirm that management sees the trajectory improving.